John Maraganore Net Worth

The estimated Net Worth of John Maraganore is at least $20 Milion dollars as of 20 May 2022. John Maraganore owns over 1,585 units of Alnylam Pharmaceuticals Inc stock worth over $7,864,633 and over the last 20 years he sold ALNY stock worth over $4,800,336. In addition, he makes $7,317,860 as Chief Executive Officer a Director at Alnylam Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Maraganore ALNY stock SEC Form 4 insiders trading

John has made over 74 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 1,585 units of ALNY stock worth $415,127 on 20 May 2022.

The largest trade he's ever made was exercising 120,000 units of Alnylam Pharmaceuticals Inc stock on 16 June 2009 worth over $57,600. On average, John trades about 17,234 units every 49 days since 2004. As of 20 May 2022 he still owns at least 30,028 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of John Maraganore stock trades at the bottom of the page.

John Maraganore biography

Dr. John M. Maraganore, Ph.D., is Chief Executive Officer, Director of the Alnylam Pharmaceuticals, Inc. Dr. Maraganore also served as our President from December 2002 to December 2007. From April 2000 to December 2002, Dr. Maraganore served as Senior Vice President, Strategic Product Development for Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited). He also serves as a director of Agios Pharmaceuticals, Inc. and Chair of the Biotechnology Industry Organization, a non-profit biotechnology trade organization. Dr. Maraganore formerly served as a director of bluebird bio, Inc. and Regulus Therapeutics Inc.

What is the salary of John Maraganore?

As the Chief Executive Officer a Director of Alnylam Pharmaceuticals Inc, the total compensation of John Maraganore at Alnylam Pharmaceuticals Inc is $7,317,860. There are no executives at Alnylam Pharmaceuticals Inc getting paid more.

How old is John Maraganore?

John Maraganore is 57, he's been the Chief Executive Officer a Director of Alnylam Pharmaceuticals Inc since 2007. There are 15 older and 2 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.

What's John Maraganore's mailing address?

John's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal a Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Complete history of John Maraganore stock trades at Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Bluebird bio Inc, Regulus Therapeutics Inc, Beam Therapeutics a Kymera Therapeutics

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director